Summarized by Masters of Longevity from Longevity Technology.
A short news article previewing early human data on an experimental oral muscle-targeting drug showing initial signs of benefit. It invites readers interested in early-stage biotech and muscle-preserving obesity treatments to learn more.
Key Takeaways
- An eight-week open-label trial of ATR-258 enrolled 13 overweight or obese participants and used three ascending dose levels.
- The study reported fat loss, increases in lean mass, and the largest signal in lower-extremity power.
- ATR-258 was well tolerated in this study and Atrogi plans a Phase 2 trial in 2027 to test muscle-sparing weight loss and sarcopenia.
